South Africa does not have a compounding industry for GLP-1 medications at the scale that existed in the United States during the shortage period. The Medicines and Related Substances Act governs pharmaceutical compounding locally, and the SAHPRA regulatory framework does not create a pathway for large-scale compounded GLP-1 production comparable to the US 503B outsourcing model. But the global crackdown matters to South African patients for several important reasons.
First, a significant number of South African patients have been ordering compounded semaglutide or tirzepatide from US-based online pharmacies and telehealth platforms — attracted by prices that can be 60–80% below the cost of branded products available through South African private prescriptions. These supply chains are now under active enforcement scrutiny. As the FDA issues warning letters and import alerts, and as pharmaceutical manufacturers pursue legal action against online distributors, the reliability and legality of these sources is diminishing rapidly.
The counterfeit API risk is the most immediate concern. The FDA’s own adverse event data shows that patients purchasing compounded GLP-1s from online sources have been hospitalised due to dosing errors and, in some cases, potentially exposed to substandard or counterfeit active ingredients. South African patients ordering from these channels have no consumer protection recourse and no way to verify the quality of what they are receiving.
Second, the US legal battle has global implications for how pharmaceutical manufacturers approach compounding worldwide. If Novo Nordisk and Eli Lilly succeed in establishing that patent rights extend to compounded copies — not just regulatory violations — that precedent may ultimately affect how health authorities in countries like South Africa approach locally-sourced alternatives.
For now, the practical advice is straightforward: GLP-1 medications in South Africa should be obtained through a registered South African pharmacist on a valid prescription from a registered South African healthcare professional. The cost is real and the access challenges are real. But the risks of the alternatives are also real — and becoming better documented by the week.
Sources
- SAHPRA. Medicines and Related Substances Act, 1965 (Act 101 of 1965), as amended
- FDA. Import alert: unverified GLP-1 active pharmaceutical ingredients. September 2025
- GLP1SA editorial analysis. June 2026